HelioLiver™ LDT
A multi-analyte, epigenomic blood test combining cell-free DNA (cfDNA) methylation patterns and protein tumour markers.
A Breakthrough in Liver Cancer Testing
HelioLiver LDT is a new, non-invasive blood test that detects DNA markers associated with a higher risk of hepatocellular carcinoma (HCC). HelioLiver LDT can be done using a simple blood draw during a regular physician visit, eliminating the need for a separate appointment at an imaging lab.
Powered by advanced AI and machine learning, HelioLiver LDT is the first blood test to use methylation to detect early-stage liver cancer, offering new hope to patients and healthcare providers. Early detection opens up more curative treatment options, improving outcomes for all.
Proven Superior to Ultrasound in the CLiMB Trial
In the pivotal CLiMB trial — a prospective, blinded, multicenter US study in 1,968 patients with cirrhosis — HelioLiver detected HCC at 76.1% sensitivity versus 44.4% for ultrasound, with non-inferior specificity. The results are now peer-reviewed and published in the Journal of Hepatology.
Elevating the Standard of Care
Guidelines recommend routine HCC surveillance for cirrhosis, typically with an ultrasound every six months. However, fewer than 20% of patients receive the recommended testing. Why?
Patient-Reported Barriers
Designed to Improve Both Patient Adherence and Sensitivity for Small Lesions
Learn How HelioLiver's Methylation Approach Overcomes Today's Surveillance Obstacles
Ordering the HelioLiver Test Is Simple and Straightforward
Order Test
Each provider is set up with an ordering process fit for their office (via TRF or EMR).
Collect Sample
The HelioLiver Collection Kit provides materials to collect and pack serum and plasma samples from each patient.
Ship It Back
A prepaid return shipping label is included in each test kit.
Wait for Analysis
Average turnaround time is 10–14 days for each sample.
Receive Report
A 'Normal' or 'Abnormal' result is given to indicate the likelihood of HCC.
Driving Patient Adherence
Routine surveillance is critical for patients to catch cancer early before it spreads. We partner with physicians to help ensure patients maintain the recommended schedule for liver cancer testing. Testing intervals for HCC surveillance consider tumour doubling time and the cost of the surveillance test. Guidelines recommend that patients at high risk for HCC, such as those with cirrhosis, undergo surveillance every six months.